Phenylbutyrate Therapy for Maple Syrup Urine Disease

NCT01529060 | Completed Phase 2 Results DMC

• 1 other identifier: H-28463
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The investigators have learned in past research that the drug phenylbutyrate can decrease the amounts of branched chain amino acids and their byproducts in the bloodstreams of healthy volunteer patients and also patients with certain disorders of protein breakdown including maple syrup urine disease. Through this study, the investigators will try to find out how well phenylbutyrate (NaPBA), also known by name brand "Buphenyl-TM", decreases BCAA and branched chain keto chain acids in the blood of patients with MSUD. The investigators hope is that through this research the investigators will be better able to treat these patients. Subjects with MSUD will take phenylbutyrate (NaPBA) in powder form for a two-week treatment period and powder placebo, a substance with no effect on the body, for a two-week treatment period. They will be given the same amount of powder and undergo the same laboratory testing during both of the two-week treatment periods. The results will be compared once the study is over.

Conditions

Maple Syrup Urine Disease

Keywords

phenylbutyrate; MSUD; Buphenyl-TM

Outcome Measures

Primary Outcomes (2)

• 0-24 Hour AUC Leucine (Samples Collected at 0, 2, 4, 8, 12, 16, 20, and 24 Hours)

  Total Leucine exposure over 24 hours was calculated by serial blood draws at times 0, 2, 4, 8, 12, 16, 20, and 24 hours

  24 Hours

• Leucine CMax 0-24 Hours

  Maximal leucine concentration in 0-24 hours

  24 hours

Study Arms (2)

Phenylbutyrate

ACTIVE COMPARATOR

Study Drug

Drug: Phenylbutyrate

Inactive Powder

PLACEBO COMPARATOR

Placebo powder

Drug: Placebo powder

Interventions

Phenylbutyrate DRUG

Dosage of phenylbutyrate powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day, the standard UCD dose studied in our preliminary studies, for 14 days.

Also known as: Buphenyl-TM

Phenylbutyrate

Placebo powder DRUG

Dosage of inactive placebo powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day for 14 days. Subjects will receive the same amount of powder for each arm of the study.

Inactive Powder

Eligibility Criteria

• Age: 3 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Must be 3 years or older at enrollment.
• Must have a diagnosis of maple syrup urine disease (MSUD) confirmed by the presence of plasma alloisoleucine (\>5 micromol/L) and/or genetic testing showing mutations in both alleles of any subunit of BCKDHA (E1alpha subunit gene, MSUD type 1A), BCKDHB (E1beta subunit gene, MSUD type 1B), or DBT (E2 subunit gene, MSUD type 2).
• Participants must have a history of compliance to diet and treatment.
• Signed informed consent by subject and/or subject's legally acceptable representative.
• Must be capable of completing study procedures, including taking oral or G- tube medication.
• Negative pregnancy test for all females of childbearing potential.
• All females of childbearing potential and all sexually active males must agree to use an acceptable method of contraception throughout the study. Appropriate contraceptive methods include hormonal contraceptives (oral, injected, implanted, or transdermal), tubal ligation, intrauterine device, hysterectomy, vasectomy, or double barrier methods. Abstinence is an acceptable form of birth control, though appropriate contraception must be used if the subject becomes sexually active.

You may not qualify if:

• May not have used sodium phenylbutyrate within 30 days of Visit 1.
• May not have an active infection (viral or bacterial) or any condition which may exacerbate their MSUD causing metabolic decompensation.
• Cannot have any clinical or laboratory abnormality of Grade 3 or greater according to the Common Terminology Criteria for Adverse Events v3.0 (CTCAE) (or for conditions not covered by the CTCAE, a severe or life-threatening toxicity).
• May not have taken any medications known to significantly affect renal clearance or to increase protein catabolism within the 24 hours prior to Visit 1.
• May not participate if they have a known hypersensitivity to phenylacetate or phenylbutyrate or creatinine levels 1.5 times or more ULN.
• Since a total of 53 mL will be drawn over Days 14 and 15 of both treatment periods, only subjects weighing more than 30 pounds can be enrolled.

Sponsors & Collaborators

• Brendan Lee: lead

Study Sites (1)

Baylor College of Medicine

Houston, Texas, 77030, United States

Location

Related Links

• Baylor College of Medicine Website

MeSH Terms

Conditions

Maple Syrup Urine Disease

Interventions

Phenylbutyrates

Condition Hierarchy (Ancestors)

Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Amino Acid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Metabolic Diseases; Nutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Acids, Carbocyclic; Carboxylic Acids; Organic Chemicals

Results Point of Contact

• Title: Alyssa Tran, BS
• Organization: Baylor

alyssat@bcm.edu

832-822-4264

Study Officials

• Brendan Lee, M.D., Ph.D.

  Baylor College of Medicine

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor, Molecular and Human Genetics

Study Record Dates

• First Submitted: February 6, 2012
• First Posted: February 8, 2012
• Study Start: February 1, 2013
• Primary Completion: September 2, 2017
• Study Completion: December 1, 2017
• Last Updated: March 19, 2019
• Results First Posted: March 6, 2019

Record last verified: 2019-03

Locations

US (1)